Tharimmune, Inc.

About Tharimmune, Inc.

Tharimmune, Inc. is a clinical-stage biotechnology company focused on developing a diverse portfolio of therapeutic candidates in immunology, inflammation, and oncology. Their mission is to advance treatments for various conditions through innovative science and technology.

Products & Services

TH104:Lead clinical-stage candidate developed via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders exposed to high-potency opioids. Also being explored for chronic pruritus in primary biliary cholangitis.

TH023:An oral anti-TNF biologic representing a new approach to treating autoimmune diseases.

Early Stage Pipeline:Includes a multispecific biologic platform targeting unique epitopes against multiple solid tumors using proprietary EpiClick™ Technology.

Specialties

Immunology Inflammation Oncology Therapeutic Development EpiClick™ Technology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 545000000 MR: - FA: approximately $545 million FAN: 545000000	D: 2025-11-06 FD: 2025-11-06	27 investors
2	RT: Private Placement T: - FT: Private Placement	A: 540000000 MR: - FA: approximately $540 million FAN: 540000000	D: 2025-11-03 FD: 2025-11-03	25 investors
3	RT: Registered Direct Public Offering T: - FT: Registered Direct Public Offering	A: 1740000 MR: - FA: $1.74 Million FAN: 1740000	D: 2025-07-23 FD: 2025-07-23	-
4	RT: Private Placement T: - FT: Private Placement	A: 2020000 MR: - FA: $2.02 million FAN: 2020000	D: 2024-12-06 FD: 2024-12-06	3 investors
5	RT: Private Placement T: - FT: Private Placement	A: 2080000 MR: - FA: 2.08 million FAN: 2080000	D: 2024-06-20 FD: 2024-06-20	3 investors
6	RT: Public Offering T: - FT: Public Offering	A: 11000000 MR: - FA: approximately $11 million FAN: 11000000	D: 2023-11-30 FD: 2023-11-30	-
7	RT: Public Offering T: - FT: Public Offering	A: 10000000 MR: - FA: $10,000,000 FAN: 10000000	D: 2023-11-27 FD: 2023-11-27	1 investors

Private Placement Latest

2025-11-06

$545.0M

27 investors (Pro only)

Private Placement 2025-11-03

$540.0M

Registered Direct Public Offering 2025-07-23

$1.7M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

V

Vincent Lopriore

Executive Chairman of Board

S

Sireesh Appajosyula

Chief Executive Officer

N

Nir Barak

Chief Medical Advisor

J

James Gordon Liddy

Independent Director

G

Gary Stetz

Independent Director

C

Clay Kahler

Independent Director

View 8 more team members with Pro

Unlock Full Team Directory

Recent News

Tharimmune, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

About Tharimmune, Inc.

Products & Services

Specialties

Funding History

Growth Metrics

Team & Leadership

Recent News

Tharimmune, Inc. Announces New Product Launch

Leadership Team Expands with Industry Veteran

Company Recognized as Industry Leader

Key Competitors

Competitor Alpha

Competitor Beta

Competitor Gamma

Competitor Delta

Company Details

Similar Companies

Technology Stack